Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

GENE - CHEMICAL INTERACTIONS REPORT

CRRD ID: 69152
Species: Homo sapiens
CRRD Object: Gene
Symbol: EGFR
Name: epidermal growth factor receptor
Acc ID: CHEBI:49668
Term: gefitinib
Definition: A member of the class of quinazolines that is quinazoline which is substituted by a (3-chloro-4-fluorophenyl)nitrilo group, 3-(morpholin-4-yl)propoxy group and a methoxy group at positions 4,6 and 7, respectively. An EGFR kinase inhibitor used for the treatment of non-small cell lung cancer.
Chemical ID: MESH:C419708
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction is comprised of a complex set of reactions and/or regulatory events, possibly involving additional chemicals and/or gene products.
QualifierEvidenceWithReferenceSourceNotesOriginal Reference(s)
affects response to substanceEXP 6480464CTDEGFR gene mutant form affects the susceptibility to Gefitinib, EGFR protein affects the susceptibility to Gefitinib, EGFR protein mutant form affects the susceptibility to Gefitinib

PMID:15976335, PMID:16243822, PMID:18271929, PMID:18771084, PMID:20846305, PMID:28739874, PMID:30237564
decreases activityEXP 6480464CTDgefitinib results in decreased activity of EGFR protein

PMID:17938326, PMID:20549698, PMID:21258428
decreases expressionEXP 6480464CTDGefitinib results in decreased expression of EGFR protein modified form

PMID:19288272, PMID:30136359
decreases phosphorylationEXP 6480464CTDGefitinib results in decreased phosphorylation of EGFR protein

PMID:13680161, PMID:14679152, PMID:17145836, PMID:17236550, PMID:17473213, PMID:28942004, PMID:29383186, PMID:30549224
decreases response to substanceEXP 6480464CTDEGFR gene mutant form results in decreased susceptibility to Gefitinib, EGFR protein mutant form results in decreased susceptibility to Gefitinib

PMID:16740687, PMID:17290066, PMID:30993382
increases response to substanceEXP 6480464CTDEGFR gene mutant form results in increased susceptibility to gefitinib, EGFR gene polymorphism results in increased susceptibility to gefitinib, EGFR protein mutant form results in increased susceptibility to gefitinib

PMID:16115929, PMID:16824645, PMID:17270025, PMID:18625569, PMID:27639429
multiple interactionsEXP 6480464CTD[[Gefitinib results in decreased activity of EGFR protein] which affects the localization of ABCG2 protein] which results in decreased export of Doxorubicin, [Gefitinib co-treated with betulin] results in decreased expression of and results in decreased phosphorylation of EGFR protein, [Gefitinib co-treated with Oxaliplatin] results in decreased phosphorylation of EGFR protein, [Gefitinib promotes the reaction [EGFR protein binds to EGFR protein]] which results in decreased activity of EGFR protein, [Gefitinib results in decreased activity of EGFR protein] which affects the localization of ABCG2 protein, [ITGB1 protein results in increased activity of EGFR protein] which results in decreased susceptibility to Gefitinib, betulinic acid promotes the reaction [Gefitinib results in decreased expression of EGFR protein modified form], EGFR gene mutant form promotes the reaction [Gefitinib results in decreased expression of SQSTM1 protein], EGFR gene mutant form promotes the reaction [Gefitinib results in increased cleavage of and results in increased activity of CASP3 protein], Gefitinib inhibits the reaction [bisphenol A promotes the reaction [EGFR protein binds to AR protein]], Gefitinib inhibits the reaction [bisphenol A promotes the reaction [EGFR protein binds to ESR2 protein]], Gefitinib inhibits the reaction [bisphenol A results in increased phosphorylation of EGFR protein], Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of EGFR protein], Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein], Gefitinib inhibits the reaction [EGF results in increased phosphorylation of and results in increased activity of EGFR protein], Gefitinib inhibits the reaction [EGF results in increased phosphorylation of EGFR protein], Gefitinib inhibits the reaction [EGFR protein results in decreased susceptibility to Docetaxel], Gefitinib inhibits the reaction [gemcitabine results in increased phosphorylation of and results in increased degradation of EGFR protein], Gefitinib inhibits the reaction [Irinotecan metabolite results in increased phosphorylation of and results in increased activity of EGFR protein], Gefitinib inhibits the reaction [Irinotecan results in increased phosphorylation of and results in increased activity of EGFR protein], Gefitinib inhibits the reaction [Tobacco Smoke Pollution results in increased phosphorylation of EGFR protein], Gefitinib promotes the reaction [EGF protein binds to EGFR protein], Gefitinib promotes the reaction [EGFR protein binds to EGFR protein], Gefitinib promotes the reaction [IGF1R protein binds to EGFR protein], Gefitinib results in decreased activity of [EGFR protein binds to EGFR protein], Gefitinib results in decreased activity of [EGFR protein binds to ERBB2 protein], Gefitinib results in decreased expression of and results in decreased phosphorylation of EGFR protein, KRAS protein affects the reaction [EGFR protein affects the susceptibility to Gefitinib], osimertinib inhibits the reaction [EGFR protein mutant form results in decreased susceptibility to Gefitinib]

PMID:13680161, PMID:15723263, PMID:16243822, PMID:17146438, PMID:17473213, PMID:17898861, PMID:17938326, PMID:18927496, PMID:19318490, PMID:21478906, PMID:21544845, PMID:21787763, PMID:24888374, PMID:27087131, PMID:27447558, PMID:27639429, PMID:28739874, PMID:29383186, PMID:30136359, PMID:30237564, PMID:30993382
decreases activityISORGD:25436480464CTDgefitinib results in decreased activity of EGFR protein

PMID:29228391
decreases expressionISORGD:25436480464CTDgefitinib results in decreased expression of EGFR protein modified form

PMID:15660382
decreases phosphorylationISORGD:25436480464CTDgefitinib results in decreased phosphorylation of EGFR protein

PMID:18375820
multiple interactionsISORGD:105116480464CTD[gefitinib results in decreased activity of EGFR protein] which results in increased susceptibility to naphthalene, gefitinib inhibits the reaction [Cadmium Chloride results in increased phosphorylation of EGFR protein], gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein], gefitinib results in decreased phosphorylation of and results in decreased activity of EGFR protein

PMID:15841081, PMID:20935109, PMID:23948867
multiple interactionsISORGD:25436480464CTDgefitinib inhibits the reaction [HBEGF protein inhibits the reaction [sodium arsenite results in decreased phosphorylation of and results in decreased activity of EGFR protein]]

PMID:29228391
Go Back to source page   Continue to Ontology report

NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.